SML1919
Nexinhib20
≥98% (HPLC), exocytosis inhibitor, powder
别名:
4,4-Dimethyl-1-(3-nitrophenyl)-2-(1H-1,2,4-triazol-1-yl)-1-penten-3-one, 4,4-Dimethyl-1-(3-nitrophenyl)-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-one
Product Name
Nexinhib20, ≥98% (HPLC)
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 20 mg/mL, clear
储存温度
2-8°C
相关类别
生化/生理作用
Inhibitor of Rab27a-JFC1 interaction; inhibitor of neutrophil exocytosis and inflammation
Nexinhib20 (neutrophil exocytosis inhibitor 20) is a potent inhibitor of the interaction between the small GTPase Rab27a and its effector JFC1 (synaptotagmin-like protein1). Nexinhib20 inhibits exocytosis of azurophilic granules in human neutrophils without affecting other important innate immune responses including phagocytosis and neutrophil extracellular trap production.
Nexinhib20 prevents the expression of cytochrome b558 in the plasma membrane. It modulates vesicular trafficking and neutrophil activities. Nexinhib20 reduces the systemic inflammation, mediated by neutrophils.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
LncRNA H19-rich extracellular vesicles derived from gastric cancer stem cells facilitate tumorigenicity and metastasis via mediating intratumor communication network.
Zhao, et al.
Journal of Translational Medicine, 21, 238-238 (2023)
Nesrin Irep et al.
Journal of cellular and molecular medicine, 28(4), e18138-e18138 (2024-02-14)
Exosomes are recognized as important mediators of cell-to-cell communication, facilitating carcinogenesis. Although there have been significant advancements in exosome research in recent decades, no drugs that target the inhibition of sEV secretion have been approved for human use. For this
Identification of Neutrophil Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation DRUGGABILITY OF THE SMALL GTPase Rab27a
Johnson J L, et al.
The Journal of Biological Chemistry, 291(50), 25965-25982 (2016)
Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors.
Wenqun Zhong et al.
Cancer research, 83(16), 2790-2806 (2023-04-28)
Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited efficacy against solid tumors, even when the targeted antigens are well expressed. A better understanding of the underlying mechanisms of
Carolina F Ruivo et al.
Gut, 71(10), 2043-2068 (2022-01-12)
Intratumor heterogeneity drives cancer progression and therapy resistance. However, it has yet to be determined whether and how subpopulations of cancer cells interact and how this interaction affects the tumour. We have studied the spontaneous flow of extracellular vesicles (EVs)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持